Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Kisspeptin/GPR54 System: What Do We Know About Its Role in Human Reproduction?

Trevisan CM, Montagna E, de Oliveira R, Christofolini DM, Barbosa CP, Crandall KA, Bianco B.

Cell Physiol Biochem. 2018;49(4):1259-1276. doi: 10.1159/000493406. Epub 2018 Sep 11. Review.

2.

Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial.

Montagna E, Bagnardi V, Cancello G, Sangalli C, Pagan E, Iorfida M, Mazza M, Mazzarol G, Dellapasqua S, Munzone E, Goldhirsch A, Colleoni M.

Breast Care (Basel). 2018 Jul;13(3):177-181. doi: 10.1159/000487630. Epub 2018 Apr 26.

PMID:
30069178
3.

Formulation, implementation and evaluation of a distance course for accreditation in patient safety.

Wanderlei PN, Montagna E.

Einstein (Sao Paulo). 2018 Jun 28;16(2):eGS4316. doi: 10.1590/S1679-45082018GS4316. English, Portuguese.

4.

Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?

Cazzaniga ME, Munzone E, Montagna E, Pappagallo G.

Expert Rev Anticancer Ther. 2018 Aug;18(8):805-814. doi: 10.1080/14737140.2018.1489244. Epub 2018 Jul 4.

PMID:
29902087
5.

Phase II Trial of Bevacizumab Plus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide With or Without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer.

Palazzo A, Dellapasqua S, Munzone E, Bagnardi V, Mazza M, Cancello G, Ghisini R, Iorfida M, Montagna E, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2018 Aug;18(4):328-335. doi: 10.1016/j.clbc.2018.01.010. Epub 2018 Feb 2.

PMID:
29486983
6.

Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey.

Carnio S, Galetta D, Scotti V, Cortinovis DL, Antonuzzo A, Pisconti S, Rossi A, Martelli O, Cecere FL, Lunghi A, Del Conte A, Montagna ES, Topulli J, Pelizzoni D, Rapetti SG, Gianetta M, Pacchiana MV, Pegoraro V, Cataldo N, Bria E, Novello S.

Support Care Cancer. 2018 Jun;26(6):1841-1849. doi: 10.1007/s00520-017-4004-1. Epub 2017 Dec 21.

PMID:
29270827
7.

Molecular basis of basal cell carcinoma.

Montagna E, Lopes OS.

An Bras Dermatol. 2017 Jul-Aug;92(4):517-520. doi: 10.1590/abd1806-4841.20176544. Review.

8.

Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes.

Montagna E, Pirola S, Maisonneuve P, De Roberto G, Cancello G, Palazzo A, Viale G, Colleoni M.

Clin Breast Cancer. 2018 Jun;18(3):e401-e405. doi: 10.1016/j.clbc.2017.07.003. Epub 2017 Jul 10.

PMID:
28778379
9.

Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.

Montagna E, Vingiani A, Maisonneuve P, Cancello G, Contaldo F, Pruneri G, Colleoni M.

Breast. 2017 Aug;34:83-88. doi: 10.1016/j.breast.2017.05.009. Epub 2017 May 23.

PMID:
28544923
10.

The Role of APP in Structural Spine Plasticity.

Montagna E, Dorostkar MM, Herms J.

Front Mol Neurosci. 2017 May 10;10:136. doi: 10.3389/fnmol.2017.00136. eCollection 2017. Review.

11.

The Relationship Between Copper, Iron, and Selenium Levels and Alzheimer Disease.

Vaz FNC, Fermino BL, Haskel MVL, Wouk J, de Freitas GBL, Fabbri R, Montagna E, Rocha JBT, Bonini JS.

Biol Trace Elem Res. 2018 Feb;181(2):185-191. doi: 10.1007/s12011-017-1042-y. Epub 2017 May 13.

PMID:
28500578
12.

Electrochemical discrimination of mints: The last Chinese emperors Kuang Hsü and Hsüan T'ung monetary unification.

Doménech-Carbó A, Doménech-Carbó MT, Montagna E, Álvarez-Romero C, Lee Y.

Talanta. 2017 Jul 1;169:50-56. doi: 10.1016/j.talanta.2017.03.025. Epub 2017 Mar 18.

PMID:
28411821
13.

Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.

Montagna E, Palazzo A, Maisonneuve P, Cancello G, Iorfida M, Sciandivasci A, Esposito A, Cardillo A, Mazza M, Munzone E, Lai A, Goldhirsch A, Colleoni M.

Cancer Lett. 2017 Aug 1;400:276-281. doi: 10.1016/j.canlet.2017.01.027. Epub 2017 Jan 26.

PMID:
28131905
14.

Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey.

Pacchiana MV, Capelletto E, Carnio S, Gridelli C, Rossi A, Galetta D, Montagna ES, Bordi P, Ceribelli A, Cortinovis D, Scotti V, Martelli O, Valmadre G, Del Conte A, Miccianza A, Morena R, Rosetti F, Di Maio M, Ostacoli L, Novello S.

Clin Lung Cancer. 2017 Jul;18(4):381-387. doi: 10.1016/j.cllc.2016.10.002. Epub 2016 Nov 22.

PMID:
27965013
15.

Correction: Systemic Delivery of Recombinant Brain Derived Neurotrophic Factor (BDNF) in the R6/2 Mouse Model of Huntington's Disease.

Giampà C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR.

PLoS One. 2016 Nov 23;11(11):e0166102. doi: 10.1371/journal.pone.0166102. eCollection 2016.

16.

Associations of Polymorphisms in Anti-Müllerian Hormone (AMH Ile49Ser) and its Type II Receptor (AMHRII -482 A>G) on Reproductive Outcomes and Polycystic Ovary Syndrome: a Systematic Review and Meta-Analysis.

Pabalan N, Montagna E, Singian E, Tabangay L, Jarjanazi H, Barbosa CP, Bianco B.

Cell Physiol Biochem. 2016;39(6):2249-2261. Epub 2016 Nov 7. Review.

17.

Amyloid precursor protein maintains constitutive and adaptive plasticity of dendritic spines in adult brain by regulating D-serine homeostasis.

Zou C, Crux S, Marinesco S, Montagna E, Sgobio C, Shi Y, Shi S, Zhu K, Dorostkar MM, Müller UC, Herms J.

EMBO J. 2016 Oct 17;35(20):2213-2222. Epub 2016 Aug 29.

18.

Ultrasound-Guided Vascular Access Simulator for Medical Training: Proposal of a Simple, Economic and Effective Model.

Fürst RV, Polimanti AC, Galego SJ, Bicudo MC, Montagna E, Corrêa JA.

World J Surg. 2017 Mar;41(3):681-686. doi: 10.1007/s00268-016-3757-x.

PMID:
27766394
19.

The advances and new technologies for the study of mitochondrial diseases.

Bianco B, Montagna E.

Einstein (Sao Paulo). 2016 Apr-Jun;14(2):291-3. doi: 10.1590/S1679-45082016MD3561. English, Portuguese.

20.

Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

Catino A, Misino A, Scattone A, Caldarola L, Petroni S, Logroscino A, Montagna ES, Serio G, Simone G, Galetta D.

Transl Lung Cancer Res. 2016 Feb;5(1):145-9. doi: 10.3978/j.issn.2218-6751.2016.01.04.

21.

Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.

Balduzzi A, Bagnardi V, Sandri MT, Dellapasqua S, Cardillo A, Montagna E, Cancello G, Iorfida M, Ghisini R, Viale G, Intra M, Luini A, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Oct;15(5):e257-62. doi: 10.1016/j.clbc.2015.03.007. Epub 2015 Apr 30.

PMID:
26362840
22.

Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Cancello G, Palazzo A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Santillo B, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Dec;15(6):440-7. doi: 10.1016/j.clbc.2015.07.003. Epub 2015 Jul 10.

PMID:
26255932
23.

Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.

Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A, Iorfida M, Viale G, Barberis M, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2015 Aug;15(4):259-65. doi: 10.1016/j.clbc.2015.03.002. Epub 2015 Mar 18.

PMID:
25933934
24.

Intraneuronal APP and extracellular Aβ independently cause dendritic spine pathology in transgenic mouse models of Alzheimer's disease.

Zou C, Montagna E, Shi Y, Peters F, Blazquez-Llorca L, Shi S, Filser S, Dorostkar MM, Herms J.

Acta Neuropathol. 2015 Jun;129(6):909-20. doi: 10.1007/s00401-015-1421-4. Epub 2015 Apr 11.

25.

Phase angle and handgrip strength are sensitive early markers of energy intake in hypophagic, non-surgical patients at nutritional risk, with contraindications to enteral nutrition.

Caccialanza R, Cereda E, Klersy C, Bonardi C, Cappello S, Quarleri L, Turri A, Montagna E, Iacona I, Valentino F, Pedrazzoli P.

Nutrients. 2015 Mar 11;7(3):1828-40. doi: 10.3390/nu7031828.

26.

Primary intraoperative transluminal angioplasty: a new approach to reduce the early failure of distal arteriovenous fistulas.

Napoli M, Lefons ML, Mangione D, Montagna C, Montagna E, Montinaro AM, Pati C, Sandri G, Sozzo E, Stefanizzi S.

J Vasc Access. 2015 May-Jun;16(3):250-4. doi: 10.5301/jva.5000327. Epub 2015 Jan 17.

PMID:
25613144
27.

Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.

Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, Balduzzi A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Casadio C, Sangalli C, Goldhirsch A, Colleoni M.

Ann Oncol. 2015 Feb;26(2):307-13. doi: 10.1093/annonc/mdu528. Epub 2014 Nov 19.

PMID:
25411418
28.

Metronomic therapy and breast cancer: a systematic review.

Montagna E, Cancello G, Dellapasqua S, Munzone E, Colleoni M.

Cancer Treat Rev. 2014 Sep;40(8):942-50. doi: 10.1016/j.ctrv.2014.06.002. Epub 2014 Jun 18. Review.

PMID:
24998489
29.

Early dropout predictive factors in obesity treatment.

Michelini I, Falchi AG, Muggia C, Grecchi I, Montagna E, De Silvestri A, Tinelli C.

Nutr Res Pract. 2014 Feb;8(1):94-102. doi: 10.4162/nrp.2014.8.1.94. Epub 2014 Jan 29.

30.

Whole-body magnetic resonance imaging, metastatic breast cancer and pregnancy: a case report.

Montagna E, Peccatori F, Petralia G, Tomasi Cont N, Iorfida M, Colleoni M.

Breast. 2014 Jun;23(3):295-6. doi: 10.1016/j.breast.2014.01.012. Epub 2014 Feb 13. No abstract available.

PMID:
24529906
31.

Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.

Balduzzi A, Bagnardi V, Rotmensz N, Dellapasqua S, Montagna E, Cardillo A, Viale G, Veronesi P, Intra M, Luini A, Pruneri G, Mastropasqua G, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2014 Aug;14(4):258-64. doi: 10.1016/j.clbc.2013.10.019. Epub 2013 Oct 26.

PMID:
24325948
32.

Pathological features and survival outcomes of very young patients with early breast cancer: how much is "very young"?

Cancello G, Maisonneuve P, Mazza M, Montagna E, Rotmensz N, Viale G, Pruneri G, Veronesi P, Luini A, Gentilini O, Goldhirsch A, Colleoni M.

Breast. 2013 Dec;22(6):1046-51. doi: 10.1016/j.breast.2013.08.006. Epub 2013 Sep 30.

PMID:
24091127
33.

Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.

Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Quarleri L, Montagna E, Foli A, Milani P, Lavatelli F, Marena C, Merlini G.

JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):891-4. doi: 10.1177/0148607113501328. Epub 2013 Sep 26.

PMID:
24072737
34.

Treatment of breast cancer in young women: do we need more aggressive therapies?

Cancello G, Montagna E.

J Thorac Dis. 2013 Jun;5 Suppl 1:S47-54. doi: 10.3978/j.issn.2072-1439.2013.06.10.

35.

The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?

Montagna E, Cancello G, Colleoni M.

Cancer Treat Rev. 2013 Dec;39(8):886-90. doi: 10.1016/j.ctrv.2013.04.007. Epub 2013 May 29. Review.

PMID:
23725877
36.

Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.

Giampà C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR.

PLoS One. 2013 May 20;8(5):e64037. doi: 10.1371/journal.pone.0064037. Print 2013. Erratum in: PLoS One. 2016 Nov 23;11(11):e0166102.

37.

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.

Leuti A, Laurenti D, Giampà C, Montagna E, Dato C, Anzilotti S, Melone MA, Bernardi G, Fusco FR.

Neurobiol Dis. 2013 Apr;52:104-16. doi: 10.1016/j.nbd.2012.11.016. Epub 2012 Dec 7.

PMID:
23220622
38.

Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.

Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, Galimberti V, Veronesi P, Luini A, Pruneri G, Bottiglieri L, Mastropasqua MG, Goldhirsch A, Viale G, Colleoni M.

Clin Breast Cancer. 2013 Feb;13(1):31-9. doi: 10.1016/j.clbc.2012.09.002. Epub 2012 Oct 24.

PMID:
23098574
39.

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M.

Ann Oncol. 2013 Mar;24(3):661-8. doi: 10.1093/annonc/mds430. Epub 2012 Sep 28.

PMID:
23022996
40.

Neoadjuvant therapy for ER-positive breast cancers.

Colleoni M, Montagna E.

Ann Oncol. 2012 Sep;23 Suppl 10:x243-8.

PMID:
22987970
41.

Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, Calleri A, Rampinelli C, Goldhirsch A, Bertolini F, Colleoni M.

Clin Breast Cancer. 2012 Jun;12(3):207-14. doi: 10.1016/j.clbc.2012.03.008. Epub 2012 Apr 20.

PMID:
22520733
42.

Invasive lobular breast cancer: subtypes and outcome.

Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, Montagna E, Dellapasqua S, Veronesi P, Galimberti V, Luini A, Goldhirsch A, Colleoni M, Viale G.

Breast Cancer Res Treat. 2012 Jun;133(2):713-23. doi: 10.1007/s10549-012-2002-z. Epub 2012 Mar 8.

PMID:
22399188
43.

Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.

Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, Goldhirsch A, Colleoni M.

Breast. 2012 Jun;21(3):309-13. doi: 10.1016/j.breast.2012.01.015. Epub 2012 Feb 16.

PMID:
22341133
44.

[A case of Xanthinuria in a patient with marked hypouricemia].

Martella V, Sozzo E, Montagna E, Stefanizzi S, Cito A, Marinello E, Terzuoli L, Micheli V, Napoli M.

G Ital Nefrol. 2011 Nov-Dec;28(6):648-53. Italian.

PMID:
22167616
45.

Outcome of special types of luminal breast cancer.

Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, Mazza M, Perri G, Iorfida M, Pruneri G, Goldhirsch A, Viale G.

Ann Oncol. 2012 Jun;23(6):1428-36. doi: 10.1093/annonc/mdr461. Epub 2011 Oct 29.

PMID:
22039080
46.

Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.

Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Montagna E, Russo P, Foli A, Milani P, Lavatelli F, Merlini G.

Ann Hematol. 2012 Mar;91(3):399-406. doi: 10.1007/s00277-011-1309-x. Epub 2011 Aug 9.

PMID:
21826471
47.

Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Cancello G, Mazza M, Cardillo A, Ghisini R, Galimberti V, Veronesi P, Monti S, Luini A, Raviele PR, Mastropasqua MG, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2011 Oct;129(3):867-75. doi: 10.1007/s10549-011-1697-6. Epub 2011 Aug 6.

PMID:
21822638
48.

Breast cancer subtypes and outcome after local and regional relapse.

Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M.

Ann Oncol. 2012 Feb;23(2):324-31. doi: 10.1093/annonc/mdr129. Epub 2011 Apr 27.

PMID:
21525402
49.

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2011 Jun;127(3):713-20. doi: 10.1007/s10549-011-1465-7. Epub 2011 Mar 31.

PMID:
21452022
50.

Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer.

Zurrida S, Montagna E, Naninato P, Colleoni M, Goldhirsch A.

Ann Oncol. 2011 Feb;22(2):479-80. doi: 10.1093/annonc/mdq688. No abstract available.

Supplemental Content

Loading ...
Support Center